Abdominal tumors (including digestive, urinary, gynecological, etc.)
Conditions
Interventions
Propofol + Remimazolam Group:Intravenous injection of sufentanil 0.3-0.5 µg/kg (60s), followed by intravenous injection of propofol 1-2 mg/kg, followed by intravenous injection of remazolam 0.1~0.2mg/
Propofol + Normal Saline Group:Intravenous injection of sufentanil 0.3-0.5 µg/kg (60s), followed by intravenous injection of propofol 1-2 mg/kg, followed by intravenous injection of 0.1~0.2mg/kg of no
Sponsors
Guangxi Medical University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1: Age >= 18 years old; 2: ASA classification grades II to III; 3: Surgical grade III to IV; 4: Scheduled abdominal surgery; 5: A tracheal intubation under general anesthesia is required; 6: The estimated operation time is >= 2 hours; 7: Postoperative patient-controlled intravenous analgesia pump for >= 48 hours; 8: Expected postoperative hospital stay of >= 5 days; 9: Be able to fully understand the process and methods of this research, voluntarily participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1: Those with contraindications to general anesthesia or who have previously experienced allergic reactions to remimazolam or its excipients; 2: There are cases of difficult airways or those that are judged to be difficult for tracheal intubation (with a modified Mallampati score of level III to IV); 3: Severe liver dysfunction (Child-Pugh grade C) or severe renal failure (requiring renal replacement therapy); 4: Patients with myasthenia gravis; 5: Severe depression state; 6: History of alcohol abuse or drug dependence; 7: Abuse or prolonged use of anesthetic, sedative and analgesic drugs; 8: Those who have a history of mental disorders, epilepsy, or hyperthyroidism/hypothyroidism in the past; 9: Select those who have participated in any drug clinical trials within the past 1 month; 10: Those who are unable to communicate due to language barriers or hearing impairments; 11: Preoperative hemoglobin (HGB) = 20% of the total blood volume.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of postoperative delirium; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence rate of cardiovascular adverse events (such as sinus bradycardia, sinus tachycardia, hypotension, hypertension, new-onset arrhythmia, etc.) during the maintenance period;The incidence of acute POD in the PACU;The incidence of postoperative agitation in the PACU;Sleep quality within 1 to 3 days after the surgery;The number of propofol rescue administrations and the average dosage (mg/kg/h) during anesthesia maintenance;Quality score at 1-3 days after surgery;The incidence of delayed awakening in the PACU;The usage rate of flumazenil in the PACU; | — |
Countries
China
Contacts
Public ContactLin Fei
Guangxi Medical University Cancer Hospital
Outcome results
None listed